Literature DB >> 26507310

Evaluating pathogenic dementia variants in posterior cortical atrophy.

Minerva M Carrasquillo1, Imelda Barber2, Sarah J Lincoln1, Melissa E Murray1, Gamze Balci Camsari3, Qurat Ul Ain Khan3, Thuy Nguyen1, Li Ma1, Gina D Bisceglio1, Julia E Crook4, Steven G Younkin1, Dennis W Dickson1, Bradley F Boeve5, Neill R Graff-Radford3, Kevin Morgan2, Nilüfer Ertekin-Taner6.   

Abstract

Posterior cortical atrophy (PCA) is an understudied visual impairment syndrome most often due to "posterior Alzheimer's disease (AD)" pathology. Case studies detected mutations in PSEN1, PSEN2, GRN, MAPT, and PRNP in subjects with clinical PCA. To detect the frequency and spectrum of mutations in known dementia genes in PCA, we screened 124 European-American subjects with clinical PCA (n = 67) or posterior AD neuropathology (n = 57) for variants in genes implicated in AD, frontotemporal dementia, and prion disease using NeuroX, a customized exome array. Frequencies in PCA of the variants annotated as pathogenic or potentially pathogenic were compared against ∼ 4300 European-American population controls from the NHLBI Exome Sequencing Project. We identified 2 rare variants not previously reported in PCA, TREM2 Arg47His, and PSEN2 Ser130Leu. No other pathogenic or potentially pathogenic variants were detected in the screened dementia genes. In this first systematic variant screen of a PCA cohort, we report 2 rare mutations in TREM2 and PSEN2, validate our previously reported APOE ε4 association, and demonstrate the utility of NeuroX.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APOE; Dementia; NeuroX; PCA; PSEN2; Posterior Alzheimer's disease; TREM2

Mesh:

Substances:

Year:  2015        PMID: 26507310      PMCID: PMC4688220          DOI: 10.1016/j.neurobiolaging.2015.09.023

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  38 in total

1.  Long-standing prion dementia manifesting as posterior cortical atrophy.

Authors:  Raphaël Depaz; Stéphane Haik; Katell Peoc'h; Danielle Seilhean; David Grabli; Savine Vicart; Marie Sarazin; Bertrand DeToffol; Catherine Remy; Catherine Fallet-Bianco; J L Laplanche; Bertrand Fontaine; Jean Philippe Brandel
Journal:  Alzheimer Dis Assoc Disord       Date:  2012 Jul-Sep       Impact factor: 2.703

2.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.

Authors:  Gernot Kleinberger; Yoshinori Yamanishi; Marc Suárez-Calvet; Eva Czirr; Ebba Lohmann; Elise Cuyvers; Hanne Struyfs; Nadine Pettkus; Andrea Wenninger-Weinzierl; Fargol Mazaheri; Sabina Tahirovic; Alberto Lleó; Daniel Alcolea; Juan Fortea; Michael Willem; Sven Lammich; José L Molinuevo; Raquel Sánchez-Valle; Anna Antonell; Alfredo Ramirez; Michael T Heneka; Kristel Sleegers; Julie van der Zee; Jean-Jacques Martin; Sebastiaan Engelborghs; Asli Demirtas-Tatlidede; Henrik Zetterberg; Christine Van Broeckhoven; Hakan Gurvit; Tony Wyss-Coray; John Hardy; Marco Colonna; Christian Haass
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

3.  Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution.

Authors:  M H Rosenbloom; A Alkalay; N Agarwal; S L Baker; J P O'Neil; M Janabi; I V Yen; M Growdon; J Jang; C Madison; E C Mormino; H J Rosen; M L Gorno-Tempini; M W Weiner; B L Miller; W J Jagust; G D Rabinovici
Journal:  Neurology       Date:  2011-04-27       Impact factor: 9.910

4.  CSF biomarkers in posterior cortical atrophy.

Authors:  J Seguin; M Formaglio; A Perret-Liaudet; I Quadrio; Y Tholance; O Rouaud; C Thomas-Anterion; B Croisile; H Mollion; O Moreaud; M Salzmann; A Dorey; M Bataillard; M-H Coste; A Vighetto; P Krolak-Salmon
Journal:  Neurology       Date:  2011-04-27       Impact factor: 9.910

5.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

Review 6.  Progranulin mutations as risk factors for Alzheimer disease.

Authors:  David C Perry; Manja Lehmann; Jennifer S Yokoyama; Anna Karydas; Jason Jiyong Lee; Giovanni Coppola; Lea T Grinberg; Dan Geschwind; William W Seeley; Bruce L Miller; Howard Rosen; Gil Rabinovici
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

7.  First report of PSEN2 mutation presenting as posterior cortical atrophy.

Authors:  Lucio Tremolizzo; Emanuela Susani; Cristina Mapelli; Valeria Isella; Francesca Bertola; Carlo Ferrarese; Ildebrando Appollonio
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jul-Sep       Impact factor: 2.703

8.  A patient with posterior cortical atrophy possesses a novel mutation in the presenilin 1 gene.

Authors:  Emilia J Sitek; Ewa Narożańska; Beata Pepłońska; Sławomir Filipek; Anna Barczak; Maria Styczyńska; Krzysztof Mlynarczyk; Bogna Brockhuis; Erik Portelius; Dorota Religa; Maria Barcikowska; Jarosław Sławek; Cezary Żekanowski
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

9.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease.

Authors:  R Sherrington; E I Rogaev; Y Liang; E A Rogaeva; G Levesque; M Ikeda; H Chi; C Lin; G Li; K Holman; T Tsuda; L Mar; J F Foncin; A C Bruni; M P Montesi; S Sorbi; I Rainero; L Pinessi; L Nee; I Chumakov; D Pollen; A Brookes; P Sanseau; R J Polinsky; W Wasco; H A Da Silva; J L Haines; M A Perkicak-Vance; R E Tanzi; A D Roses; P E Fraser; J M Rommens; P H St George-Hyslop
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

10.  Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease.

Authors:  Celeste Sassi; Rita Guerreiro; Raphael Gibbs; Jinhui Ding; Michelle K Lupton; Claire Troakes; Safa Al-Sarraj; Michael Niblock; Jean-Marc Gallo; Jihad Adnan; Richard Killick; Kristelle S Brown; Christopher Medway; Jenny Lord; James Turton; Jose Bras; Kevin Morgan; John F Powell; Andrew Singleton; John Hardy
Journal:  Neurobiol Aging       Date:  2014-06-16       Impact factor: 4.673

View more
  4 in total

1.  Relationship of APOE, age at onset, amyloid and clinical phenotype in Alzheimer disease.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Jonathan Graff-Radford; Nilufer Ertekin-Taner; Mary M Machulda; Joseph R Duffy; Christopher G Schwarz; Matthew L Senjem; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2021-08-25       Impact factor: 5.133

2.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases.

Authors:  Cornelis Blauwendraat; Faraz Faghri; Lasse Pihlstrom; Joshua T Geiger; Alexis Elbaz; Suzanne Lesage; Jean-Christophe Corvol; Patrick May; Aude Nicolas; Yevgeniya Abramzon; Natalie A Murphy; J Raphael Gibbs; Mina Ryten; Raffaele Ferrari; Jose Bras; Rita Guerreiro; Julie Williams; Rebecca Sims; Steven Lubbe; Dena G Hernandez; Kin Y Mok; Laurie Robak; Roy H Campbell; Ekaterina Rogaeva; Bryan J Traynor; Ruth Chia; Sun Ju Chung; John A Hardy; Alexis Brice; Nicholas W Wood; Henry Houlden; Joshua M Shulman; Huw R Morris; Thomas Gasser; Rejko Krüger; Peter Heutink; Manu Sharma; Javier Simón-Sánchez; Mike A Nalls; Andrew B Singleton; Sonja W Scholz
Journal:  Neurobiol Aging       Date:  2017-05-17       Impact factor: 4.673

3.  Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease.

Authors:  Jonathan M Schott; Sebastian J Crutch; Minerva M Carrasquillo; James Uphill; Tim J Shakespeare; Natalie S Ryan; Keir X Yong; Manja Lehmann; Nilufer Ertekin-Taner; Neill R Graff-Radford; Bradley F Boeve; Melissa E Murray; Qurat Ul Ain Khan; Ronald C Petersen; Dennis W Dickson; David S Knopman; Gil D Rabinovici; Bruce L Miller; Aida Suárez González; Eulogio Gil-Néciga; Julie S Snowden; Jenny Harris; Stuart M Pickering-Brown; Eva Louwersheimer; Wiesje M van der Flier; Philip Scheltens; Yolande A Pijnenburg; Douglas Galasko; Marie Sarazin; Bruno Dubois; Eloi Magnin; Daniela Galimberti; Elio Scarpini; Stefano F Cappa; John R Hodges; Glenda M Halliday; Lauren Bartley; Maria C Carrillo; Jose T Bras; John Hardy; Martin N Rossor; John Collinge; Nick C Fox; Simon Mead
Journal:  Alzheimers Dement       Date:  2016-03-15       Impact factor: 21.566

Review 4.  TREM2 in Neurodegenerative Diseases.

Authors:  Taylor R Jay; Victoria E von Saucken; Gary E Landreth
Journal:  Mol Neurodegener       Date:  2017-08-02       Impact factor: 14.195

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.